Compare MTDR & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTDR | TMDX |
|---|---|---|
| Founded | 2003 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 4.6B |
| IPO Year | 2011 | 2019 |
| Metric | MTDR | TMDX |
|---|---|---|
| Price | $55.94 | $129.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | $59.67 | ★ $152.33 |
| AVG Volume (30 Days) | ★ 1.8M | 757.9K |
| Earning Date | 05-26-2026 | 06-01-2026 |
| Dividend Yield | ★ 2.73% | N/A |
| EPS Growth | N/A | ★ 382.18 |
| EPS | ★ 6.09 | 4.87 |
| Revenue | ★ $3,696,277,000.00 | $605,494,000.00 |
| Revenue This Year | N/A | $24.12 |
| Revenue Next Year | $10.58 | $18.69 |
| P/E Ratio | ★ $9.04 | $28.89 |
| Revenue Growth | 5.46 | ★ 37.13 |
| 52 Week Low | $35.19 | $62.42 |
| 52 Week High | $55.60 | $156.00 |
| Indicator | MTDR | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 72.38 | 42.98 |
| Support Level | $41.12 | $124.45 |
| Resistance Level | N/A | $142.44 |
| Average True Range (ATR) | 2.01 | 8.65 |
| MACD | 0.38 | 0.04 |
| Stochastic Oscillator | 94.37 | 8.58 |
Matador Resources Co is an independent energy company engaged in the exploration, development, production, and acquisition of oil and natural gas resources. The majority of the company's assets are located in the United States, with an emphasis on oil and natural gas shale and other unconventional plays. Along with maintaining a portfolio of oil and natural gas properties, Matador works to identify and develop midstream opportunities that support and enhance its exploration and development business. The Company has two reportable business segments: exploration and production and midstream.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.